Sanofi Japan’s Moulding Confident On New SGLT2 Inhibitor
This article was originally published in PharmAsia News
Executive Summary
Sanofi Japan president Jez Moulding expressed confidence at an April 2 press conference about the early market penetration of the company’s new SGLT2 inhibitor Apleway (tofogliflozin), to be released later this year.